Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors

BACKGROUND: Molecularly targeted therapies using receptor inhibitors, small molecules or monoclonal antibodies are routinely applied in oncology. Verification of target expression should be mandatory prior to initiation of therapy, yet, determining the expression status is most challenging in recurr...

Descripción completa

Detalles Bibliográficos
Autores principales: Schäfer, Niklas, Gielen, Gerrit H., Rauschenbach, Laurèl, Kebir, Sied, Till, Andreas, Reinartz, Roman, Simon, Matthias, Niehusmann, Pitt, Kleinschnitz, Christoph, Herrlinger, Ulrich, Pietsch, Torsten, Scheffler, Björn, Glas, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425567/
https://www.ncbi.nlm.nih.gov/pubmed/30894200
http://dx.doi.org/10.1186/s12967-019-1846-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425567/
https://www.ncbi.nlm.nih.gov/pubmed/30894200
http://dx.doi.org/10.1186/s12967-019-1846-y

Ejemplares similares